kwality pharmaceuticals delivered robust financial performance in FY26, achieving its three-year target of doubling revenue from ₹250 crore in FY23 to ₹503 crore in the latest fiscal year. Consolidated revenue from operations grew nearly 36% year-on-year to ₹503 crore, up from ₹370 crore in FY25. This top-line expansion was accompanied by accelerated profitability growth; Profit After Tax (PAT) surged almost 69% to ₹67.3 crore from ₹39.8 crore in the previous year. The company’s PAT margins improved from 10.8% to 13.4%, while EBITDA margins expanded by approximately 200 basis points to 24%, reflecting operating leverage and a richer product mix.

The financial results were filed pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015. M/s Vijay Mehra & Co., the statutory auditors, issued an unqualified opinion on the standalone and consolidated financial statements. The Board of Directors convened the 43rd Annual General Meeting on August 31, 2026, via Video Conferencing/Other Audio Visual Means (OAVM). Remote e-voting was facilitated by NSDL, with the voting period running from August 28, 2026, to August 30, 2026. The cut-off date for determining eligibility was August 24, 2026.

Despite strong profitability, the company faced working capital headwinds due to geopolitical conflicts in the Middle East and West Asia, which disrupted supply chains and delayed customer payments. Debtor days remained elevated at 208 during much of FY26. However, management tightened inventory management and payables, successfully reducing the overall cash conversion cycle from 208 days to 170 days. Standalone trade receivables stood at ₹28,121.97 lakh as of March 31, 2026, compared to ₹15,590.00 lakh in the prior year. The company also recognized an exceptional item of ₹82.94 lakh relating to past service cost for gratuity liability due to changes in wage definitions under new Labour Codes.

Looking ahead, Kwality Pharmaceuticals raised its FY27 revenue guidance to over ₹700 crore, up from the earlier estimate of ₹650 crore. The company aims to scale profitability in tandem with this growth. Long-term, the management targets doubling revenue again over the next three years, aiming for a topline of ₹1,000 crore plus by FY29. Strategic initiatives include a large-scale bioequivalence programme spanning more than 40 oral solid dosage molecules and development of three monoclonal antibodies. The first biologic, Erythropoietin (Kwalipoietin), achieved successful pre-clinical outcomes and is on track for a CY2027 launch.

What the Numbers Show

The divergence between revenue growth and receivable accumulation warrants attention. While revenue grew 36%, standalone trade receivables more than doubled from ₹15,590.00 lakh to ₹28,121.97 lakh. This suggests that a significant portion of the top-line growth has not yet converted into cash, likely due to the delayed payments cited by management. Consequently, net cash flow from operating activities declined sharply to ₹1,699.99 lakh in FY26 from ₹5,277.37 lakh in FY25. Investors should monitor whether the improved cash conversion cycle noted in Q1 FY27 persists as the company scales toward its ₹700 crore FY27 target.

Kwality Pharmaceuticals has fixed the book closure period from August 25, 2026, to August 31, 2026, to determine shareholders eligible for its 43rd Annual General Meeting (AGM). The company will conduct the AGM via Video Conferencing (VC) or Other Audio Visual Means (OAVM) on August 31, 2026, at 12:00 noon. Shareholders holding equity shares as of the cut-off date of August 24, 2026, will be entitled to participate in electronic voting and receive dividend entitlements, if declared.

The Register of Members and Share Transfer Books will remain closed during this period pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A separate cut-off date of July 31, 2026, was established earlier to determine shareholders eligible to receive the AGM notice. This procedural step ensures that only those holding shares on the specified record dates can exercise voting rights or claim benefits associated with the meeting.

Voting Timeline and Mechanism

Electronic voting will be facilitated through the National Securities Depository Limited (NSDL) platform in compliance with Regulation 44 of the SEBI (LODR) Regulations, 2015. The voting window opens at 09:00 A.M. on August 28, 2026, and closes at 5:00 P.M. on August 30, 2026. Rishi Mittal has been appointed as the Scrutinizer for the e-voting process to ensure transparency and compliance with regulatory standards.

Key Agenda Items

Shareholders will vote on several governance resolutions approved by the Board during its meeting on August 8, 2026. The Board also approved the financial results for FY26 under Section 134 of the Companies Act, 2013. Key items requiring shareholder ratification include:

• Reappointment of Whole Time Director: Aditya Arora is proposed for reappointment as Whole Time Director for five consecutive years, from September 30, 2026, to September 29, 2031. He oversees production, quality assurance, and regulatory filings.
• Regularization of Independent Director: Swanith Kapoor, initially appointed as an Additional Director (Independent) on June 2, 2026, seeks regularization for a five-year term ending May 31, 2031.
• Retiring Directors: Aditya Arora and Anju Arora are retiring by rotation under Section 152(6) of the Companies Act, 2013, and have offered themselves for reappointment.
• Cost Auditor Remuneration: M/s Verma Khushwinder & Co. Cost Accountants (FRN: 000469) were appointed as Cost Auditors for FY27. Their remuneration requires shareholder ratification.

The disclosure was made pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, and SEBI Master Circular HO/49/14/14(7)2025-FD POD2/I/3762/2026 dated January 30, 2026.